Small-cell lung cancers in patients who never smoked cigarettes

Journal of Thoracic Oncology

Volumn 9, Issue 6, 2014, Pages 892-896

  Varghese, Anna M ^a,b   Zakowski, Maureen F ^b,c   Yu, Helena A ^a,b   Won, Helen H ^a,c   Riely, Gregory J ^a,b   Krug, Lee M ^a,b   Kris, Mark G ^a,b   Rekhtman, Natasha ^c   Ladanyi, Marc ^a,c   Wang, Lu ^c   Berger, Michael F ^a,c   Pietanza, M Catherine ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Department of Pathology ^*  (United States)

Author keywords

Never smokers; Small cell lung cancer

Indexed keywords

ERLOTINIB; RETINOBLASTOMA PROTEIN; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CBL PROTEIN; CBL PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GNAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P53; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; RAS PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; AGED; ALK GENE; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CBL GENE; EGFR GENE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENOTYPE; GNAS GENE; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYCL1 GENE; ONCOGENE; ONCOGENE K RAS; P53 GENE; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RB1 GENE; SMOKING; TERT GENE; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; SECOND CANCER; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE REARRANGEMENT; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; QUINAZOLINES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SMOKING; SURVIVAL RATE; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901474861     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000142     Document Type: Article

References (16)

1. Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 2009;4:37-43.
2. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
3. Morinaga R, Okamoto I, Furuta K, et al. Sequential occurrence of non- small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007;58:411-413. (Pubitemid 350051499)
4. Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small- cell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-215. (Pubitemid 44050422)
5. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-2247.
6. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403. (Pubitemid 41149655)
7. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
8. Li AR, Chitale D, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008;10:242-248. (Pubitemid 351692167)
9. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013;8:346-351.
10. Modi S, Kubo A, Oie H, Coxon AB, Rehmatulla A, Kaye FJ. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 2000;19:4632-4639.
11. Vallières E, Shepherd FA, Crowley J, et al.; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:1049-1059.
12. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012;18:1167-1176.
13. Rekhtman N, Marchetti A, Lau C, et al. Analysis of EGFR and KRAS mutations in small cell carcinoma and large cell neuroendocrine carcinoma of lung. 14th Annual World Conference on Lung Cancer. Amsterdam, The Netherlands; 2011.
14. D'Angelo SP, Pietanza MC. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther 2010;10: 1-10.
15. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-1116.
16. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-1110.